This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced gastrointestinal stromal tumor who have exhausted all currently approved standard anti-cancer treatment options. BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily. Cycles will be repeated until patients are no longer clinically benefiting from therapy due to disease progression, adverse events, or another discontinuation criterion.
Safety, tolerability and efficacy of BBI503 will be assessed for the duration of study treatment.

开始日期2017-03-13

申办/合作机构

Sumitomo Pharma America, Inc.

NCT02232646 / Withdrawn临床2期

A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

This is an open label, multi-center, Phase II study of BBI503 administered to adult patients with selected advanced urologic malignancies. The primary objective of this study is to evaluate the disease control rate of patients with renal cell cancer and urothelial carcinoma treated with BBI503.

开始日期2017-01-01

申办/合作机构

Sumitomo Pharma America, Inc.

NCT02483247 / Completed临床1期

A Phase Ib/II Clinical Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the study is to determine the safety, tolerability, and RP2D of BBI503 in combination with each of the selected anti-cancer agents.

开始日期2015-09-01

申办/合作机构

Sumitomo Pharma America, Inc.

100 项与 Amcasertib 相关的临床结果

登录后查看更多信息

100 项与 Amcasertib 相关的转化医学

登录后查看更多信息

100 项与 Amcasertib 相关的专利（医药）

登录后查看更多信息

项与 Amcasertib 相关的文献（医药）

Medical Oncology

Cancer stemness kinase inhibitor amcasertib: a promising therapeutic agent in ovarian cancer stem and cancer cell models with different genetic profiles

Article

作者: Asik, Aycan ; Guler Kara, Hale ; Gunduz, Cumhur ; Ozates, Neslihan Pinar

Ovarian cancer, often referred to as the 'silent killer,' is a significant contributor to mortality rates. Emerging evidence implicates Nanog as a potential therapeutic target in ovarian cancer. Amcasertib (BBI-503) is an orally administered primary class stemness kinase inhibitor that effectively targets NANOG and various cancer stem cell pathways by specifically inhibiting serine-threonine stemness kinases. This study aimed to evaluate the antineoplastic effects of Nanog inhibition, a critical transcription factor associated with pluripotency and its role in ovarian cancer tumorigenesis, using the novel therapeutic agent Amcasertib in ovarian cancer cells characterized by distinct genetic profiles. The cytotoxicity of Amcasertib was assessed in both ovarian cancer and cancer stem cell models utilizing the Xelligence-RTCA system. The impact of the determined IC50 dose on apoptosis, invasion, migration, epithelial-mesenchymal transition (EMT), cell cycle progression, colony formation, and spheroid growth was evaluated using appropriate analytical techniques. Our findings revealed that Amcasertib exhibited significant antiproliferative effects and induced apoptosis in ovarian cancer and cancer stem cells. Moreover, Amcasertib caused G1 phase arrest and impeded colony formation in MDAH-2774 cells. Additionally, Amcasertib effectively inhibited spheroid growth in OVCAR-3 and OCSC cells. Notably, it demonstrated the ability to suppress invasion and migration in MDAH-2774 and OCSC cells. Furthermore, the suppression of Nanog-mediated stem cell-like features by Amcasertib was particularly pronounced in ER-negative ovarian cancer and cancer stem cells, highlighting its high anticancer efficacy in this subgroup. These results suggest that Amcasertib holds promise as a potential standalone or combination therapy agent for the treatment of ER-negative ovarian cancer.

100 项与 Amcasertib 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10903	-	-	DB14866

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性卵巢癌	临床2期	美国	Sumitomo Pharma America, Inc.	2015-06-01
肝胆癌	临床2期	加拿大	Sumitomo Pharma America, Inc.	2015-02-01
胆管癌	临床2期	-	Boston Biomedical Associates LLC	-
胆管癌	临床2期	-	北京强新生物科技有限公司	-
胆管癌	临床2期	-	Boston Biomedical Associates LLC	-
胆管癌	临床2期	-	北京强新生物科技有限公司	-
肝细胞癌	临床2期	-	北京强新生物科技有限公司	-
肝细胞癌	临床2期	-	Boston Biomedical Associates LLC	-
肝细胞癌	临床2期	-	北京强新生物科技有限公司	-
肝细胞癌	临床2期	-	Boston Biomedical Associates LLC	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02432690 (CTgov)	临床2期	复发性卵巢癌	13	BBI503	製廠獵積廠網觸衊艱齋(衊鹹願獵構觸醖獵鏇顧) = 齋廠壓鏇構餘蓋構簾選鏇願鏇鬱膚窪範選醖餘 (廠鑰獵選憲積築壓襯衊, 積遞築膚構艱鬱簾齋淵 ~ 繭窪選鏇襯壓齋構衊構) 更多	-	2022-08-29
NCT01781455 (ASCO2017)	临床1/2期	晚期头颈癌	21	Amcasertib	(鏇繭繭壓壓獵齋鹽膚簾) = 憲獵鬱構觸餘艱構獵壓構願構壓壓積淵膚構顧 (廠獵蓋構蓋選窪夢衊醖 ) 更多	-	2017-05-30
NCT01781455 (ASCO2017)	临床1/2期	腺样囊性癌	14	Amcasertib	(構構醖憲糧艱窪膚糧鑰) = 壓顧夢網製醖選醖鏇製廠膚簾壓遞齋窪淵齋齋 (築糧製齋蓋憲鹽淵糧顧 ) 更多	-	2017-05-30
NCT01781455 (ASCO2016)	临床1期	晚期头颈癌	33	BB503	(艱遞憲廠築窪廠鬱窪憲) = Grade 3 AE included rapidly reversible diarrhea (n = 5) and nausea/vomiting (n = 1) 範遞網憲鏇壓壓鏇壓製 (淵選鑰襯齋憲積選餘齋 )	积极	2016-05-20
NCT01781455 (ASCO2015)	临床1期	晚期结直肠腺癌	47	BBI503 monotherapy	(膚夢網獵觸廠膚鹹鹹憲) = 醖鏇窪構壓壓獵網膚憲網鹽獵膚窪淵膚鑰積齋 (襯繭鬱繭餘簾憲鹹鹹網 )	-	2015-05-20
NCT01781455 (ASCO2014)	临床1期	HR阳性/HER2低表达实体瘤	26	BBI503	(淵繭糧窪壓鑰衊鏇鑰築) = 襯糧簾選製糧窪網選糧憲選鹽選齋鹹憲齋衊醖 (範鹹夢鹹鹹鹽衊積衊壓 ) 更多	-	2014-05-20